# FDA 483 - Hina Budhwani - October 24, 2025

Source: https://www.keypedia.com/records/483/hina-budhwani/4dc5ffd6-1b0f-44f5-b4de-f7a557b7eea6

> FDA 483 for Hina Budhwani on October 24, 2025. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Hina Budhwani
- Inspection Date: 2025-10-24
- Product Type: drugs
- Office Name: Dallas District Office
- Summary: An FDA inspection of Hina S. Budhwani, MD, Clinical Investigator in Houston, TX, revealed one observation related to the conduct of an investigation. The firm failed to adhere to the investigational plan by not maintaining the required waiting period between doses for subjects in a clinical protocol. This indicates a deviation from established study procedures.

## Related Officers

- [Habacuc V. Barrera](https://www.keypedia.com/people/habacuc-v-barrera/d4149e5b-7424-4ab8-b7f1-23988c83d9cf)

Company: https://www.keypedia.com/companies/hina-budhwani/b46402a3-5aab-4e07-a73c-4bfe6c1858c3

Office: https://www.keypedia.com/offices/dallas-district-office/2d1ee9ae-c44c-4494-8186-a920a69b98f9